大隐静脉曲张三种治疗方式的14年随机对照试验结果
该随机对照试验比较了高位结扎剥脱术(HLS)、腔内激光消融术(EVLA)和超声引导泡沫硬化剂治疗(UGFS)治疗症状性大隐静脉反流的长期结局。14年随访显示,UGFS的大隐静脉反流复发率和再干预率均显著高于HLS和EVLA,而后两者表现相当,各组生活质量无显著差异。
要点
- UGFS的大隐静脉反流复发风险显著高于HLS和EVLA。
- UGFS的大隐静脉再干预风险显著高于HLS和EVLA。
- HLS与EVLA在反流复发和再干预方面表现相当,生活质量各组无差异。
核心结论
- UGFS在大隐静脉反流复发和再干预率方面劣于HLS和EVLA。
- HLS和EVLA在这些结局上表现相当。
- 长期生活质量在各组间相当。
研究设计与样本
- 随机对照试验,患者按1:1:1随机分配至HLS、EVLA或UGFS。
- 主要结局为膝上大隐静脉反流和大隐静脉再干预率,次要结局包括生活质量。
主要发现
- UGFS后大隐静脉反流发生率为30.8%(12/39),HLS后为2.6%(1/38),EVLA后为6.1%(3/49),总体p < .001。
- UGFS vs HLS的GSV反流复发风险比RR 11.7(95%CI 1.6 - 85.6),UGFS vs EVLA的RR 5.0(95%CI 1.5 - 16.6)。
- UGFS后GSV再干预率为56.4%,HLS后为13.2%,EVLA后为8.2%,总体p < .001。
- UGFS vs HLS的再干预风险比RR 4.3(95%CI 1.8 - 10.2),UGFS vs EVLA的RR 6.9(95%CI 2.6 - 18.4)。
- 新生血管形成率三组无差异(HLS 29.0%,EVLA 22.5%,UGFS 23.1%,总体p = .76)。
关键数值与推荐
- Aberdeen静脉曲张问卷评分中位数(IQR):HLS 8.9(3.7, 13.3),EVLA 6.1(0.8, 12.2),UGFS 8.8(4.1, 13.4),总体p = .21。
- 中位差值:HLS vs EVLA +2.8,HLS vs UGFS +0.1,EVLA vs UGFS -2.7。
临床怎么用
- 对于症状性大隐静脉反流,UGFS的长期复发和再干预风险较高,选择时应考虑。
- HLS和EVLA在长期反流控制和再干预方面效果相当,均可作为可选方案。
- 长期生活质量在各治疗组间无显著差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare high ligation and stripping (HLS), endovenous laser ablation (EVLA), and ultrasound guided foam sclerotherapy (UGFS) for symptomatic great saphenous vein (GSV) reflux in the long term, given the limited comparative data beyond ten years. METHODS: Patients with symptomatic GSV reflux were randomised (1:1:1) to undergo HLS, EVLA, or UGFS. One hundred and ninety-six patients treated at Helsinki University Hospital were invited to 14 year follow up. Primary outcomes were above knee GSV reflux and GSV re-intervention rates. Secondary outcomes included quality of life. RESULTS: Of 233 randomised patients, 214 were included. UGFS increased the risk of GSV reflux recurrence compared with both HLS (risk ratio [RR] 11.7, 95% confidence interval [CI] 1.6 - 85.6) and EVLA (RR 5.0, 95% CI 1.5 - 16.6; 30.8% [12 of 39] after UGFS vs. 2.6% [one of 38] and 6.1% [three of 49] after HLS and EVLA, respectively; overall p < .001). UGFS was associated with a higher risk of GSV re-interventions compared with HLS (RR 4.3, 95% CI 1.8 - 10.2) and EVLA (RR 6.9, 95% CI 2.6 - 18.4; 56.4% for UGFS vs. 13.2% for HLS and 8.2% for EVLA; overall p < .001). Neovascularisation rates did not differ between the treatments (29.0%, 22.5%, and 23.1% for HLS, EVLA, and UGFS, respectively; overall p = .76). Aberdeen Varicose Vein Questionnaire scores were comparable across the groups (median [interquartile range] 8.9 [3.7, 13.3] in HLS, 6.1 [0.8, 12.2] in EVLA, and 8.8 [4.1, 13.4] in UGFS, with median differences of +2.8 [HLS vs. EVLA], +0.1 [HLS vs. UGFS], and -2.7 [EVLA vs. UGFS]; overall p = .21). CONCLUSION: UGFS demonstrated inferior outcomes in terms of GSV recurrent reflux and re-intervention rates compared with both HLS and EVLA, whereas HLS and EVLA showed comparable performance across these outcomes. Long term quality of life was comparable across all groups.
引用
- Rahman T, Noronen K, Vähäaho S, et al. Fourteen Year Outcomes of a Randomised Controlled Trial Comparing Endovenous Laser Ablation, High Ligation and Stripping, and Ultrasound Guided Foam Sclerotherapy for Great Saphenous Varicose Veins. Eur J Vasc Endovasc Surg. 2026. PMID: 41633433. doi:10.1016/j.ejvs.2026.01.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。